Drug Development

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Articles

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

Biomanufacturing: Demand for Continuous Bioprocessing Increasing

With new tests showing NDMA levels increase under normal storage conditions, FDA calls for removal of ranitidine products from the market.

FDA Removes Ranitidine Products from Market

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Understanding formulation properties early in development can prevent some costly issues later on.


A Little Thought Goes a Long Way in Tableting

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Tools help improve understanding of excipient risk in formulating OSD drugs.

Mitigating Risk in Formulating with Excipients

Understanding European GMPs and new rules from China for excipients are crucial for formulating solid-dosage drugs. 

Considering Excipient Regulations

In light of the current COVID-19 pandemic, the agencies co-chaired the first global regulators meeting to facilitate development of vaccines against SARS-CoV-2, which causes COVID-19.

FDA, EMA Collaborate on SARS-CoV-2 Vaccine Development

Emergent BioSolutions will help develop and manufacture an oral vaccine candidate and will develop plasma-based antibody therapeutics.

Emergent BioSolutions to Manufacture Oral Vaccine and Develop Antibody Therapeutics for COVID-19

Synairgen, a respiratory drug discovery and development company, has announced that it has received expedited approvals to conduct a trial of its inhaled formulation of interferon-beta-1a, SNG001, in COVID-19 patients.


UK Company Starts Trials of Inhaled Formulation for COVID-19

The partners have initiated an observational case-control study of siltuximab in patients with COVID-19 who have developed serious respiratory complications.

Eusa Pharma Partners with Italy’s Papa Giovanni XXIII Hospital to Study Siltuximab as Potential COVID-19 Treatment

An NIH study of a COVID-19 vaccine is enrolling Seattle-based healthy adult volunteers.

Formulation and Drug Delivery